PAPER Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, Gianni L, Baselga J, Bell R, Jackisch C, Cameron D, Dowsett M, Barrios CH, Steger G, Huang CS, Andersson M, Inbar M, Lichinitser M, Láng I, Nitz U, Iwata H, Thomssen C, Lohrisch C, Suter TM, Rüschoff J, Suto T, Greatorex V, Ward C, Straehle C, McFadden E, Dolci MS, Gelber RD,

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.

N Engl J Med. 2005 Oct 20;353(16):1659-72. PubMed: 16236737

PAPER Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Tu D, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Therasse P, Palmer MJ, Pater JL

A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.

N Engl J Med. 2003 Nov 6;349(19):1793-802. PubMed: 14551341

Ron Petersen on “Morris Land Maze” Reveals Early Loss of Spatial Memory in MCI

COMMENT This is an interesting approach to the assessment of early diagnostic tests for AD. As for the MCI aspect of the study, I think it is a nice demonstration of deficits in spatial memory in amnestic MCI, which certainly would be consistent with the underlyi

Ron Petersen

Mayo Clinic
United States

Drug Discovery for Neurodegenerative Disease 2007

CONFERENCE COVERAGE SERIES New York: Can Academia and Industry Work Hand-in-Glove? New York: Back to School—R and D in Academia New York: So Many Targets, So Little Time New York: Better Living Through Chemistry? New York: The Nose, Your Magic Portal? Drug Discovery for Neurodegene

Clinical Trial Data: Fit for Public Consumption

COMMUNITY NEWS 2007-03-13 Community News This week, two independent groups of academic researchers call for more transparency in the conduct of clinical trials. One focuses on the structure of industry-academic partnerships in clinical trials, while the other argues for a more ope

New York: The Nose, Your Magic Portal?

CONFERENCE COVERAGE 2007-03-13 Conference Coverage William Frey of the University of Minnesota in Minneapolis believes in the BBB. Rather than dealing with the pesky obstacle, though, he’s trying an end run around it. His route of choice is the nose, where his work suggests one gains a

PAPER Brayne C

The elephant in the room- healthy brains in later life, epidemiology and public health.

Nat Rev Neurosci. 2007 Mar;8(3):233-9. PubMed: 17299455

Kevin Booth

Pfizer
Collegeville, United States

MAP2a + MAP2b

ANTIBODY monoclonal manufacturer Cat# MAB378 immunogen = bovine MAP2 liquid, ascites detects 300kDa MAP2a & 280 kDa MAP2b only others not tested IgG₁ MAPs Chemicon and Upstate are Millipore Mouse Amphibian (various) Bovine Quail Human Mo

MAP2 (5F9)

ANTIBODY monoclonal 5F9 manufacturer Cat# 05-346 immunogen = purified rat brain MAP2 protein-G purified liquid, phosphate buffer, azide MAP2 others not tested IgG₁ MAPs Upstate and Chemicon are Millipore Mouse Rabbit Human Mouse Rat MAP2 htt

MAP1LC3 A

ANTIBODY polyclonal manufacturer Cat# AB15412 immunogen = synthetic peptide corresponding to a region within the N-terminus of human MAP1LC3 A protein serum, lyophilized Microtubule associated proteins 1A/1B light chain 3A others not tested MAPs Chemicon and Upsta

MAP1LC3 C

ANTIBODY polyclonal manufacturer Cat# AB15414 immunogen = synthetic peptide corresponding to a region within the N-terminus of human MAP1LC3 C protein serum, lyophilized Microtubule associated proteins 1A/1B light chain 3C others not tested MAPs Chemicon and Upsta

MAP2 (AP20)

ANTIBODY monoclonal AP20 manufacturer Cat# MAB3418X<br />Reference: <br /><a href="/papers/astrocytes-expressing-als-linked-mutated-sod1-release-factors-selectively-toxic-motor-neurons" target="_new">Nagai, 2007</a> <

MAP2

ANTIBODY polyclonal manufacturer Cat# IHCR1004-6 immunogen = purified rat brain MAP liquid, diluted, purified, PBS, Tween, ProClin, ready to use MAP2; recognizes all MAP2 isoforms (MAP2A, MAP2B, MAP2C and MAP2D). It shows greatest immunoreactivity with the HMW-MAP